ClinConnect ClinConnect Logo
Search / Trial NCT04362592

In-Utero Endoscopic Correction of Spina Bifida

Launched by UNIVERSITY OF SOUTHERN CALIFORNIA · Apr 22, 2020

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to treat spina bifida, a condition that affects the spine and can cause various health issues. The study will test two different surgical methods performed on unborn babies to see which is more effective and safe. The goal is to make it easier for doctors to correct the condition before birth, which could improve health outcomes for the baby.

To be eligible for this study, mothers must be at least 18 years old and between 19 and 27 weeks pregnant. The unborn baby must have a specific form of spina bifida confirmed by imaging tests. Participants will need to attend follow-up appointments after the surgery to monitor their health and the baby's development. It's important for potential participants to have a good support system in place and to be able to comply with travel requirements for follow-up care. This trial is currently recruiting, so if you think you might qualify and are interested, it could be worth discussing with your healthcare provider.

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • 1. Myelomeningocele (including myeloschisis) at level T1 through S1 with hindbrain herniation. Lesion level and hindbrain herniation will be confirmed by MRI and ultrasonography.
  • 2. Maternal age ≥18 years.
  • 3. Gestational age of 19 to 27 6/7 weeks' gestation as determined by clinical information and evaluation of first ultrasound.
  • 4. Balanced karyotype and/or normal mircoarray with written confirmation of culture results. Results by fluorescence in situ hybridization (FISH) will be acceptable if the patient is at 24 weeks or more.
  • 5. Positive evaluation of social work consult indicating the patient is capable of consenting to the procedure and has the appropriate social support system to participate in the study.
  • 6. Positive evaluation from pediatric neurology consult.
  • 7. Willing to return to our center, or to a multi-disciplinary spina bifida clinic closer to their home for the 6, 12, 24, 30, 48, and 60 months follow-up evaluations.
  • Exclusion Criteria:
  • 1. Multiple gestation
  • 2. Insulin-dependent pregestational diabetes
  • 3. Presence of a fetal anomaly not related to Chiari II Malformation. A fetal echocardiogram will be conducted before surgery and if the finding is abnormal, the patient will be excluded.
  • 4. Fetal kyphosis of 30 degrees or more, assessed by ultrasound or MRI.
  • 5. Presence of uterine cervical cerclage or history of incompetent cervix.
  • 6. Placenta previa or placental abruption.
  • 7. Short cervix \< 25 mm measured by cervical ultrasound.
  • 8. Obesity as defined by body mass index (BMI) of 40 or greater.
  • 9. History of previous spontaneous singleton delivery prior to 37 weeks.
  • 10. Maternal-fetal Rh isoimmunization, Kell sensitization or a history of neonatal alloimmune thrombocytopenia.
  • 11. Maternal HIV or Hepatitis-B status positive because of the increased risk of transmission to the fetus during maternal-fetal surgery. If the patient's HIV or Hepatitis B status is unknown, the patient must be tested and found to have negative results before she can be enrolled.
  • 12. Known Hepatitis-C positivity. If the patient's Hepatitis C status is unknown, she does not need to be screened.
  • 13. Uterine anomaly such as large (greater than 6 cm) fibroids, cervical fibroids or multiple fibroids or Mullerian duct abnormality.
  • 14. Other maternal medical condition which is a contraindication to surgery or anesthesia.
  • 15. Patient does not have a support person (e.g., husband, partner, parents).
  • 16. Inability to comply with the travel and follow-up requirements of the study.
  • 17. Patient does not meet psychosocial criteria as determined by the social worker evaluation.
  • 18. Participation in another intervention study that influences maternal and fetal morbidity and mortality.
  • 19. Maternal hypertension as determined by the investigator, which would increase the risk of preeclampsia or preterm delivery (including, but not limited to: uncontrolled hypertension, chronic hypertension with end organ damage and new onset hypertension in current pregnancy).
  • 20. Bicornuate uterus or any other uterine malformation the PI decides is not safe for surgery.
  • 21. Nickel allergy.
  • 22. Maternal request to undergo open fetal surgery for the antenatal correction of OSB at our institution primarily or after failed fetoscopic approach.
  • 23. Known maternal hypersensitivity to bovine collagen or chondroitin materials.

About University Of Southern California

The University of Southern California (USC) is a prestigious research institution located in Los Angeles, California, known for its commitment to advancing knowledge and innovation in various fields, including medicine and health sciences. As a clinical trial sponsor, USC leverages its extensive resources, interdisciplinary expertise, and state-of-the-art facilities to conduct cutting-edge research aimed at improving patient outcomes and public health. The university fosters collaboration among its diverse faculty and students, ensuring a dynamic environment for the development and implementation of clinical studies that adhere to the highest ethical and scientific standards. Through its clinical trials, USC aims to contribute to the advancement of medical science and the translation of research findings into practical applications that benefit communities locally and globally.

Locations

Los Angeles, California, United States

Pasadena, California, United States

Wellington, Florida, United States

Patients applied

0 patients applied

Trial Officials

Ruben Quintero, MD

Principal Investigator

US Fetus

Ramen Chmait, MD

Principal Investigator

University of Southern California

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials